Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fortress Biotech

1.71
+0.01000.59%
Post-market: 1.68-0.0300-1.75%16:45 EDT
Volume:131.07K
Turnover:222.56K
Market Cap:47.20M
PE:-0.50
High:1.74
Open:1.68
Low:1.66
Close:1.70
Loading ...

Mustang Bio Announces Closing of $8 Million Public Offering

GlobeNewswire
·
10 Feb

Mustang Bio Announces Pricing of $8 Million Public Offering

THOMSON REUTERS
·
06 Feb

Mustang Bio Announces Pricing of $8 Million Public Offering

GlobeNewswire
·
06 Feb

Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex

TipRanks
·
28 Jan

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce Cmv Events in Recipients of Hsct

THOMSON REUTERS
·
27 Jan

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

GlobeNewswire
·
27 Jan

Fortress Biotech Inc - FDA Extends Target Action Date for Cutx-101 Nda to September 30, 2025

THOMSON REUTERS
·
17 Jan

Mustang Bio Inc - Stock to Begin Trading on Split-Adjusted Basis Jan 16, 2025

THOMSON REUTERS
·
14 Jan

Mustang Bio Announces Reverse Stock Split

GlobeNewswire
·
14 Jan

Fortress Biotech (FBIO) Gets a Buy from Roth MKM

TIPRANKS
·
08 Jan

BRIEF-Fortress Biotech And Cyprium Therapeutics Announce U.S. FDA Acceptance And Priority Review Of NDA For CUTX-101

Reuters
·
06 Jan

Fortress Biotech Inc - FDA Sets Pdufa Target Action Date for Cutx-101 on June 30, 2025

THOMSON REUTERS
·
06 Jan

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Cutx-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

THOMSON REUTERS
·
06 Jan

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of Nda for Cutx-101 for Treatment of Menkes Disease

THOMSON REUTERS
·
06 Jan

Fortress Biotech Inc - FDA Grants Priority Review for Cutx-101, Pdufa Date June 30, 2025

THOMSON REUTERS
·
06 Jan

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

GlobeNewswire
·
06 Jan